Why Type 2 Diabetes May Be Several Different Conditions

A single label of type 2 diabetes can sit on top of several biologically different conditions that raise blood sugar through different routes. Two people can receive the same diagnosis and the same first prescription while their bodies are doing almost opposite things underneath. One may be running low on insulin because the cells that make it are tiring early. Another may be making plenty of insulin while the body refuses to listen. Recognizing that difference sits at the heart of a precision-medicine view of diabetes, and it shapes how I think about the question every patient quietly asks: why me, and why this.

Is type 2 diabetes really one disease?

For most of the last century, we sorted diabetes into a few boxes. There was the autoimmune form that usually appears young, and then everything else, which we called type 2 and treated as a single entity defined mostly by high glucose. That framing was useful and saved lives. It also hid a lot.

A more honest definition is this. Type 2 diabetes is a shared end point, a sustained rise in blood sugar, that several different underlying problems can produce. Glucose is the smoke, and the fire can start in more than one place.

It helps to picture blood sugar control as a balance between two forces. On one side is how much insulin your pancreas can release. On the other is how well your muscle, liver, and fat respond to it. Diabetes shows up when that balance breaks, and the side that gives way tells you something real about the person in front of you.

What are the different ways diabetes can develop?

Think of two broad failure modes, with a wide spectrum in between. The first is a problem of supply. The beta cells in the pancreas, whose job is to make insulin, do not keep up. In some people they were never quite robust, often for reasons written into their genes. My doctoral research at the Lund University Diabetes Centre has been about exactly this layer, the genetics that shape how well a person secretes insulin. The secretion side is not one thing either, since different genetic variants nudge insulin release in their own ways.

The second failure mode is a problem of response. Here the pancreas may be working hard, even overworking, but the tissues have grown deaf to insulin. This is insulin resistance, and it often travels with extra weight around the middle and a fatty liver. The insulin is there; the signal does not arrive.

Most people sit between these poles, with some loss of supply and some loss of response. But where you sit matters, because it can shape how early you were diagnosed and how your glucose answers different treatments.

How can two people with the same diagnosis be so different?

Consider a thin woman in her forties whose blood sugar drifted up despite a careful life, and a heavier man in his fifties whose diabetes arrived alongside high blood pressure and a family history of heart disease. Both will likely be told they have type 2 diabetes. Yet her problem may lean toward an early shortfall of insulin, while his leans toward tissues that resist it. Same words on the chart, two different stories, and different risks. A picture dominated by insulin resistance and central weight tends to pull cardiovascular and liver problems forward, while one dominated by early insulin shortfall can move a person toward needing insulin support sooner. Knowing the lean of the disease helps a clinician anticipate what to watch for.

Decades of careful research have reshaped the field here. By taking large groups of people with diabetes and looking at several routine measurements at once, including age at diagnosis, body shape, markers of insulin secretion and resistance, and antibody status, investigators have found that people fall into recognizable groupings rather than scatter at random. I will not put numbers on these groupings, because the boundaries are still being refined and differ across populations. But the qualitative finding is durable. The cloud of patients has structure: some sit near early insulin shortage, some near heavy insulin resistance, and others near milder patterns that often track with age.

Why do these subtypes matter for treatment?

Because the underlying mechanism decides which lever works. If the core problem is that tissues ignore insulin, a strategy aimed at the insulin-resistance side, including care that addresses weight and metabolic load, tends to make biological sense. If the core problem is a pancreas running low, leaning hard on a drug that squeezes more insulin out of tired beta cells may give a short reward and a longer cost. Matching the approach to the mechanism is not exotic medicine. It is simply working with the biology instead of against it.

The company a disease keeps matters too. When diabetes arrives wrapped in cardiovascular and kidney risk, the modern instinct, supported by strong outcome trials, is to choose therapies that protect those organs, not only ones that move the glucose number.

None of this is a reason to self-diagnose your subtype or change anything on your own. This is educational, not medical advice, and the right next step is a conversation with your own clinician who can see the full picture.

What does precision medicine actually change?

I have circled this idea from several directions. In genetics at Lund, I have studied why insulin secretion varies between people. As a research fellow in systems medicine at Stanford with Professor Atul Butte, I worked on reading large clinical datasets for signal a single visit can miss. In building EASY Diabetes, where I serve as Head of Medical and Science, we put that thinking into a tool clinicians use in the room. In our randomized trial, EASY-1, the system was evaluated against standard care, partly by helping match the right next move to the person.

The through-line is simple to say and hard to do. The label type 2 diabetes confirms that the glucose problem is real. The work of good care is to learn which mechanism is driving it in a given person and respond to that, rather than to the diagnosis alone.